June 10, 2016
Takeda Pharmaceutical has gained the global rights to develop and commercialize Dublin-based Theravance Biopharma’s TD-8954, an investigational treatment for gastrointestinal motility disorders, the companies said. Under their deal, announced on June 8, the Japanese drug giant will make an upfront...read more